Post-earnings recap
Reported
Thu, Mar 12, 2026
EPS actual
$-1.78
EPS est.
$-2.76
EPS surprise
+35.46%
1-day move
-4.05%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a larger-than-expected loss per share, which surprised investors positively despite the overall negative sentiment. The stock fell by 4.05% following the announcement, reflecting concerns over the lack of revenue details and future guidance. Investors may be cautious as the company navigates its strategic initiatives without clear direction for the upcoming quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.78 | N/A | +35.46% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced in the quarter and emphasized the importance of their ongoing strategic initiatives. They did not provide any forward guidance, leaving investors without clear expectations.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on strategic initiatives despite the current challenges.